Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma
Some patients with COPD present with significant reversibility of airflow limitation after receiving bronchodilation therapy. Leukotriene B4 (LTB4) has been implicated in the pathophysiology of both COPD and asthma. We tested the hypothesis that COPD patients with airflow reversibility and asthmatic...
Gespeichert in:
| Veröffentlicht in: | Chest 2005-05, Vol.127 (5), p.1553-1559 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1559 |
|---|---|
| container_issue | 5 |
| container_start_page | 1553 |
| container_title | Chest |
| container_volume | 127 |
| creator | Kostikas, Konstantinos Gaga, Mina Papatheodorou, Georgios Karamanis, Thomas Orphanidou, Dora Loukides, Stelios |
| description | Some patients with COPD present with significant reversibility of airflow limitation after receiving bronchodilation therapy. Leukotriene B4 (LTB4) has been implicated in the pathophysiology of both COPD and asthma. We tested the hypothesis that COPD patients with airflow reversibility and asthmatic patients who smoke might have similar levels of LTB4 in exhaled breath condensate (EBC) and sputum supernatant. The repeatability and stability of LTB4 measurements were additionally studied.
Prospective, cross-sectional study.
We studied 30 patients with COPD (15 smokers [FEV1, 56% predicted; SD, 6% predicted]; 15 patients with significant reversibility in airway obstruction after bronchodilation [FEV1, 14% predicted; SD, 2% predicted]). Fifteen asthmatic patients who smoked, with similar FEV1 and reversibility were also studied. Ten healthy smokers served as control subjects.
A hospital research laboratory.
Spirometry and reversibility testing were performed on the first visit. On the following day, EBC was collected for the measurement of LTB4, and induced sputum was collected for differential cell counts and LTB4 measurement in the sputum supernatant.
LTB4 levels in EBC [mean (SD)] were increased in COPD patients (mean, 86.7 pg/mL; SD, 19 pg/mL) and asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL) compared to control subjects (mean, 32.3 pg/mL; SD, 10 pg/mL; p < 0.0001 for both groups). COPD patients with airflow reversibility (mean, 99.8 pg/mL; SD, 12 pg/mL) had values similar to those of asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL; p = 0.2) and higher than those of COPD patients without airflow reversibility (mean, 73.7 pg/mL; SD, 17 pg/mL; p = 0.002). Similar results were observed in the sputum supernatant. Measurements of LTB4 in EBC and sputum were repeatable on two consecutive days, but measurements in the frozen samples of EBC and sputum were not stable after 3 weeks.
Patients with asthma and reversible COPD presented with higher LTB4 values compared to patients with nonreversible COPD and healthy smokers. This difference may be mainly attributed to the presence of reversibility in airway obstruction, probably as part of a common underlying inflammatory process. |
| doi_str_mv | 10.1378/chest.127.5.1553 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67820609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0012369215347188</els_id><sourcerecordid>67820609</sourcerecordid><originalsourceid>FETCH-LOGICAL-e246t-2786f295591e68b1b5dc34a3ea8d7920d4f82125ed76ee09a587dd1d49d184d23</originalsourceid><addsrcrecordid>eNpNkUtv1DAUhS0EokNhzwplA7sMfsQvdu1QHtJIrVQQS8tj3yEuiTPYDo9_j9MZBN5cWfq-szgHoecErwmT6rXrIZc1oXLN14Rz9gCtiGakZbxjD9EKY0JbJjQ9Q09yvsP1T7R4jM4IV_VRuUJuC_O3qaQAEZrLrgmxufrV2wF8c5nAlr7ZTNFDzLZAY6Nvbg9zmcfmdj5AirbYWBbnxpaaUHLzJSzK9c3be_gil360T9GjvR0yPDvdc_T53dWnzYd2e_3-4-Zi2wLtRGmpVGJPNeeagFA7suPesc4ysMpLTbHv9ooSysFLAYC15Up6T3ynPVGdp-wcvTrmHtL0fa7NmDFkB8NgI0xzNkIqigXWFXxxAufdCN4cUhht-m3-1lKBlyfAZmeHfbLRhfyPE5JTwpYgfOT68LX_GRKYPNphqLHM3G9zN821paEuZLhZFqrKm6MCtYkfAZLJrlbnwFfdFeOnYAg2y7zHCPOf_AcE3JY_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67820609</pqid></control><display><type>article</type><title>Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Kostikas, Konstantinos ; Gaga, Mina ; Papatheodorou, Georgios ; Karamanis, Thomas ; Orphanidou, Dora ; Loukides, Stelios</creator><creatorcontrib>Kostikas, Konstantinos ; Gaga, Mina ; Papatheodorou, Georgios ; Karamanis, Thomas ; Orphanidou, Dora ; Loukides, Stelios</creatorcontrib><description>Some patients with COPD present with significant reversibility of airflow limitation after receiving bronchodilation therapy. Leukotriene B4 (LTB4) has been implicated in the pathophysiology of both COPD and asthma. We tested the hypothesis that COPD patients with airflow reversibility and asthmatic patients who smoke might have similar levels of LTB4 in exhaled breath condensate (EBC) and sputum supernatant. The repeatability and stability of LTB4 measurements were additionally studied.
Prospective, cross-sectional study.
We studied 30 patients with COPD (15 smokers [FEV1, 56% predicted; SD, 6% predicted]; 15 patients with significant reversibility in airway obstruction after bronchodilation [FEV1, 14% predicted; SD, 2% predicted]). Fifteen asthmatic patients who smoked, with similar FEV1 and reversibility were also studied. Ten healthy smokers served as control subjects.
A hospital research laboratory.
Spirometry and reversibility testing were performed on the first visit. On the following day, EBC was collected for the measurement of LTB4, and induced sputum was collected for differential cell counts and LTB4 measurement in the sputum supernatant.
LTB4 levels in EBC [mean (SD)] were increased in COPD patients (mean, 86.7 pg/mL; SD, 19 pg/mL) and asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL) compared to control subjects (mean, 32.3 pg/mL; SD, 10 pg/mL; p < 0.0001 for both groups). COPD patients with airflow reversibility (mean, 99.8 pg/mL; SD, 12 pg/mL) had values similar to those of asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL; p = 0.2) and higher than those of COPD patients without airflow reversibility (mean, 73.7 pg/mL; SD, 17 pg/mL; p = 0.002). Similar results were observed in the sputum supernatant. Measurements of LTB4 in EBC and sputum were repeatable on two consecutive days, but measurements in the frozen samples of EBC and sputum were not stable after 3 weeks.
Patients with asthma and reversible COPD presented with higher LTB4 values compared to patients with nonreversible COPD and healthy smokers. This difference may be mainly attributed to the presence of reversibility in airway obstruction, probably as part of a common underlying inflammatory process.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.127.5.1553</identifier><identifier>PMID: 15888827</identifier><identifier>CODEN: CHETBF</identifier><language>eng</language><publisher>Northbrook, IL: Elsevier Inc</publisher><subject>Adult ; Aged ; asthma ; Asthma - diagnosis ; Biological and medical sciences ; Breath Tests ; Cardiology. Vascular system ; Chronic obstructive pulmonary disease, asthma ; COPD ; Cross-Sectional Studies ; Diagnosis, Differential ; exhaled breath condensate ; Humans ; induced sputum ; leukotriene B4 ; Leukotriene B4 - analysis ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Prospective Studies ; Pulmonary Disease, Chronic Obstructive - diagnosis ; reversibility ; Sputum - chemistry</subject><ispartof>Chest, 2005-05, Vol.127 (5), p.1553-1559</ispartof><rights>2005 The American College of Chest Physicians</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16752139$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15888827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><creatorcontrib>Gaga, Mina</creatorcontrib><creatorcontrib>Papatheodorou, Georgios</creatorcontrib><creatorcontrib>Karamanis, Thomas</creatorcontrib><creatorcontrib>Orphanidou, Dora</creatorcontrib><creatorcontrib>Loukides, Stelios</creatorcontrib><title>Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma</title><title>Chest</title><addtitle>Chest</addtitle><description>Some patients with COPD present with significant reversibility of airflow limitation after receiving bronchodilation therapy. Leukotriene B4 (LTB4) has been implicated in the pathophysiology of both COPD and asthma. We tested the hypothesis that COPD patients with airflow reversibility and asthmatic patients who smoke might have similar levels of LTB4 in exhaled breath condensate (EBC) and sputum supernatant. The repeatability and stability of LTB4 measurements were additionally studied.
Prospective, cross-sectional study.
We studied 30 patients with COPD (15 smokers [FEV1, 56% predicted; SD, 6% predicted]; 15 patients with significant reversibility in airway obstruction after bronchodilation [FEV1, 14% predicted; SD, 2% predicted]). Fifteen asthmatic patients who smoked, with similar FEV1 and reversibility were also studied. Ten healthy smokers served as control subjects.
A hospital research laboratory.
Spirometry and reversibility testing were performed on the first visit. On the following day, EBC was collected for the measurement of LTB4, and induced sputum was collected for differential cell counts and LTB4 measurement in the sputum supernatant.
LTB4 levels in EBC [mean (SD)] were increased in COPD patients (mean, 86.7 pg/mL; SD, 19 pg/mL) and asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL) compared to control subjects (mean, 32.3 pg/mL; SD, 10 pg/mL; p < 0.0001 for both groups). COPD patients with airflow reversibility (mean, 99.8 pg/mL; SD, 12 pg/mL) had values similar to those of asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL; p = 0.2) and higher than those of COPD patients without airflow reversibility (mean, 73.7 pg/mL; SD, 17 pg/mL; p = 0.002). Similar results were observed in the sputum supernatant. Measurements of LTB4 in EBC and sputum were repeatable on two consecutive days, but measurements in the frozen samples of EBC and sputum were not stable after 3 weeks.
Patients with asthma and reversible COPD presented with higher LTB4 values compared to patients with nonreversible COPD and healthy smokers. This difference may be mainly attributed to the presence of reversibility in airway obstruction, probably as part of a common underlying inflammatory process.</description><subject>Adult</subject><subject>Aged</subject><subject>asthma</subject><subject>Asthma - diagnosis</subject><subject>Biological and medical sciences</subject><subject>Breath Tests</subject><subject>Cardiology. Vascular system</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>COPD</subject><subject>Cross-Sectional Studies</subject><subject>Diagnosis, Differential</subject><subject>exhaled breath condensate</subject><subject>Humans</subject><subject>induced sputum</subject><subject>leukotriene B4</subject><subject>Leukotriene B4 - analysis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Prospective Studies</subject><subject>Pulmonary Disease, Chronic Obstructive - diagnosis</subject><subject>reversibility</subject><subject>Sputum - chemistry</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkUtv1DAUhS0EokNhzwplA7sMfsQvdu1QHtJIrVQQS8tj3yEuiTPYDo9_j9MZBN5cWfq-szgHoecErwmT6rXrIZc1oXLN14Rz9gCtiGakZbxjD9EKY0JbJjQ9Q09yvsP1T7R4jM4IV_VRuUJuC_O3qaQAEZrLrgmxufrV2wF8c5nAlr7ZTNFDzLZAY6Nvbg9zmcfmdj5AirbYWBbnxpaaUHLzJSzK9c3be_gil360T9GjvR0yPDvdc_T53dWnzYd2e_3-4-Zi2wLtRGmpVGJPNeeagFA7suPesc4ysMpLTbHv9ooSysFLAYC15Up6T3ynPVGdp-wcvTrmHtL0fa7NmDFkB8NgI0xzNkIqigXWFXxxAufdCN4cUhht-m3-1lKBlyfAZmeHfbLRhfyPE5JTwpYgfOT68LX_GRKYPNphqLHM3G9zN821paEuZLhZFqrKm6MCtYkfAZLJrlbnwFfdFeOnYAg2y7zHCPOf_AcE3JY_</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Kostikas, Konstantinos</creator><creator>Gaga, Mina</creator><creator>Papatheodorou, Georgios</creator><creator>Karamanis, Thomas</creator><creator>Orphanidou, Dora</creator><creator>Loukides, Stelios</creator><general>Elsevier Inc</general><general>American College of Chest Physicians</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma</title><author>Kostikas, Konstantinos ; Gaga, Mina ; Papatheodorou, Georgios ; Karamanis, Thomas ; Orphanidou, Dora ; Loukides, Stelios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e246t-2786f295591e68b1b5dc34a3ea8d7920d4f82125ed76ee09a587dd1d49d184d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>asthma</topic><topic>Asthma - diagnosis</topic><topic>Biological and medical sciences</topic><topic>Breath Tests</topic><topic>Cardiology. Vascular system</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>COPD</topic><topic>Cross-Sectional Studies</topic><topic>Diagnosis, Differential</topic><topic>exhaled breath condensate</topic><topic>Humans</topic><topic>induced sputum</topic><topic>leukotriene B4</topic><topic>Leukotriene B4 - analysis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Prospective Studies</topic><topic>Pulmonary Disease, Chronic Obstructive - diagnosis</topic><topic>reversibility</topic><topic>Sputum - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kostikas, Konstantinos</creatorcontrib><creatorcontrib>Gaga, Mina</creatorcontrib><creatorcontrib>Papatheodorou, Georgios</creatorcontrib><creatorcontrib>Karamanis, Thomas</creatorcontrib><creatorcontrib>Orphanidou, Dora</creatorcontrib><creatorcontrib>Loukides, Stelios</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kostikas, Konstantinos</au><au>Gaga, Mina</au><au>Papatheodorou, Georgios</au><au>Karamanis, Thomas</au><au>Orphanidou, Dora</au><au>Loukides, Stelios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2005-05</date><risdate>2005</risdate><volume>127</volume><issue>5</issue><spage>1553</spage><epage>1559</epage><pages>1553-1559</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><coden>CHETBF</coden><abstract>Some patients with COPD present with significant reversibility of airflow limitation after receiving bronchodilation therapy. Leukotriene B4 (LTB4) has been implicated in the pathophysiology of both COPD and asthma. We tested the hypothesis that COPD patients with airflow reversibility and asthmatic patients who smoke might have similar levels of LTB4 in exhaled breath condensate (EBC) and sputum supernatant. The repeatability and stability of LTB4 measurements were additionally studied.
Prospective, cross-sectional study.
We studied 30 patients with COPD (15 smokers [FEV1, 56% predicted; SD, 6% predicted]; 15 patients with significant reversibility in airway obstruction after bronchodilation [FEV1, 14% predicted; SD, 2% predicted]). Fifteen asthmatic patients who smoked, with similar FEV1 and reversibility were also studied. Ten healthy smokers served as control subjects.
A hospital research laboratory.
Spirometry and reversibility testing were performed on the first visit. On the following day, EBC was collected for the measurement of LTB4, and induced sputum was collected for differential cell counts and LTB4 measurement in the sputum supernatant.
LTB4 levels in EBC [mean (SD)] were increased in COPD patients (mean, 86.7 pg/mL; SD, 19 pg/mL) and asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL) compared to control subjects (mean, 32.3 pg/mL; SD, 10 pg/mL; p < 0.0001 for both groups). COPD patients with airflow reversibility (mean, 99.8 pg/mL; SD, 12 pg/mL) had values similar to those of asthmatic patients (mean, 97.5 pg/mL; SD, 15 pg/mL; p = 0.2) and higher than those of COPD patients without airflow reversibility (mean, 73.7 pg/mL; SD, 17 pg/mL; p = 0.002). Similar results were observed in the sputum supernatant. Measurements of LTB4 in EBC and sputum were repeatable on two consecutive days, but measurements in the frozen samples of EBC and sputum were not stable after 3 weeks.
Patients with asthma and reversible COPD presented with higher LTB4 values compared to patients with nonreversible COPD and healthy smokers. This difference may be mainly attributed to the presence of reversibility in airway obstruction, probably as part of a common underlying inflammatory process.</abstract><cop>Northbrook, IL</cop><pub>Elsevier Inc</pub><pmid>15888827</pmid><doi>10.1378/chest.127.5.1553</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-3692 |
| ispartof | Chest, 2005-05, Vol.127 (5), p.1553-1559 |
| issn | 0012-3692 1931-3543 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67820609 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged asthma Asthma - diagnosis Biological and medical sciences Breath Tests Cardiology. Vascular system Chronic obstructive pulmonary disease, asthma COPD Cross-Sectional Studies Diagnosis, Differential exhaled breath condensate Humans induced sputum leukotriene B4 Leukotriene B4 - analysis Male Medical sciences Middle Aged Pneumology Prospective Studies Pulmonary Disease, Chronic Obstructive - diagnosis reversibility Sputum - chemistry |
| title | Leukotriene B4 in Exhaled Breath Condensate and Sputum Supernatant in Patients With COPD and Asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A56%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leukotriene%20B4%20in%20Exhaled%20Breath%20Condensate%20and%20Sputum%20Supernatant%20in%20Patients%20With%20COPD%20and%20Asthma&rft.jtitle=Chest&rft.au=Kostikas,%20Konstantinos&rft.date=2005-05&rft.volume=127&rft.issue=5&rft.spage=1553&rft.epage=1559&rft.pages=1553-1559&rft.issn=0012-3692&rft.eissn=1931-3543&rft.coden=CHETBF&rft_id=info:doi/10.1378/chest.127.5.1553&rft_dat=%3Cproquest_pubme%3E67820609%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67820609&rft_id=info:pmid/15888827&rft_els_id=S0012369215347188&rfr_iscdi=true |